Hyundai Bioscience
Seoul · Founded 2000
About Hyundai Bioscience
Hyundai Bioscience develops methods for putting drugs into the body via drug delivery technology. Their organic-inorganic hybrid technologies, a patented technique, are a drug delivery system that makes use of inorganic compounds as drug carriers to enable the transport of bioactive molecules, such as low-molecular compounds, genes, or medicinal medicines, to target areas. Chemical anti-cancer medications are given polymer carrier technology to reduce toxicity and curb adverse effects.
Company Facts
- Founded: 2000
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $58.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2025)
- Ticker: kosdaq:048410
- Website: http://www.hyundaibioscience.com/en
- Phone: 82 70 7008 0114
Industries & Categories
Biotechnology, Electrical Distribution
Canonical: https://fsome.com/organization/hyundai-bioscience-201424 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.